Incidence and Survival of Epithelial Ovarian, Fallopian Tube, Peritoneal, and Undesignated Abdominal/pelvic Cancers in Sweden 1960-2014: A Population-based Cohort Study

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2021 Apr 27

PMID 33902507

Citations 2

Authors

Pia Leandersson

Thomas Hogberg

Paul W Dickman

Susanne Malander

Christer Borgfeldt

Affiliations

Soon will be listed here.

Abstract

Background: Despite improved surgical and oncological treatment, ovarian cancer continues to be the most lethal of the gynecologic malignancies. We aimed to analyze survival trends in epithelial ovarian cancer with regard to age, tumor site, and morphology in Sweden 1960 to 2014.

Methods: A nationwide population-based study was conducted using data from the Swedish Cancer Registry on 46,350 women aged 18 or older with a diagnosis of epithelial ovarian, fallopian tube, peritoneal, or undesignated abdominal/pelvic cancer 1960 to 2014. Analyses of age-standardized incidence and relative survival (RS) were performed and time trends modelled according to age, tumor site, and morphology.

Results: Overall incidence of ovarian, tubal, peritoneal, and undesignated abdominal/pelvic cancers declined since 1980. Median age at diagnosis increased. Serous carcinoma increased in incidence. RS at 1, 2 and 5 years from diagnosis improved since 1960, although not for the youngest and the oldest patients. Ten-year RS did not improve. The best RS was found for fallopian tube cancer and the worst RS for undesignated abdominal/pelvic cancer. Among the morphologic subgroups, endometrioid carcinoma had the best RS.

Conclusions: Survival in epithelial ovarian, tubal, peritoneal, and undesignated abdominal/pelvic cancers in Sweden has improved over the last six decades. Advances in epithelial ovarian cancer treatment have extended life for the first 5 years from diagnosis but 10-year survival remains poor.

Citing Articles

Survival in Elderly Ovarian Cancer Remains Challenging in the Nordic Countries.

Hemminki K, Zitricky F, Forsti A, Hemminki A Cancers (Basel). 2024; 16(12).

PMID: 38927904 PMC: 11201377. DOI: 10.3390/cancers16122198.

Downregulated Dual-Specificity Protein Phosphatase 1 in Ovarian Carcinoma: A Comprehensive Study With Multiple Methods.

Liang Z, He R, Luo J, Huang Z, Li J, Zhong L Pathol Oncol Res. 2022; 28:1610404.

PMID: 35911442 PMC: 9336223. DOI: 10.3389/pore.2022.1610404.

References

Fago-Olsen C, Hogdall C, Kehlet H, Christensen I, Ottesen B . Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey. Acta Obstet Gynecol Scand. 2011; 90(3):273-9. DOI: 10.1111/j.1600-0412.2010.01043.x. View

Timmermans M, Sonke G, Van de Vijver K, van der Aa M, Kruitwagen R . No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. Eur J Cancer. 2017; 88:31-37. DOI: 10.1016/j.ejca.2017.10.030. View

Barlow L, Westergren K, Holmberg L, Talback M . The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2008; 48(1):27-33. DOI: 10.1080/02841860802247664. View

Kurman R, Shih I . Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol. 2011; 42(7):918-31. PMC: 3148026. DOI: 10.1016/j.humpath.2011.03.003. View

Corazziari I, Quinn M, Capocaccia R . Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004; 40(15):2307-16. DOI: 10.1016/j.ejca.2004.07.002. View

Smith J, RUTLEDGE F, DELCLOS L . Postoperative treatment of early cancer of the ovary: a random trial between postoperative irradiation and chemotherapy. Natl Cancer Inst Monogr. 1975; 42:149-53. View

Jareid M, Thalabard J, Aarflot M, Bovelstad H, Lund E, Braaten T . Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol. 2018; 149(1):127-132. DOI: 10.1016/j.ygyno.2018.02.006. View

Gauthier J, Wu Q, Gooley T . Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. Bone Marrow Transplant. 2019; 55(4):675-680. DOI: 10.1038/s41409-019-0679-x. View

McCluggage W . Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011; 43(5):420-32. DOI: 10.1097/PAT.0b013e328348a6e7. View

10.

Vergote I, Trope C, Amant F, Kristensen G, Ehlen T, Johnson N . Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363(10):943-53. DOI: 10.1056/NEJMoa0908806. View

11.

Baldwin L, Huang B, Miller R, Tucker T, Goodrich S, Podzielinski I . Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012; 120(3):612-8. DOI: 10.1097/AOG.0b013e318264f794. View

12.

Wright J, Chen L, Tergas A, Patankar S, Burke W, Hou J . Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol. 2015; 125(6):1345-1352. PMC: 4484269. DOI: 10.1097/AOG.0000000000000854. View

13.

Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-33. DOI: 10.1001/jama.288.3.321. View

14.

Skirnisdottir I, Garmo H, Wilander E, Holmberg L . Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer. 2008; 123(8):1897-901. DOI: 10.1002/ijc.23724. View

15.

Riopel M, Ronnett B, Kurman R . Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol. 1999; 23(6):617-35. DOI: 10.1097/00000478-199906000-00001. View

16.

Lim D, Murali R, Murray M, Veras E, Park K, Soslow R . Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors. Am J Surg Pathol. 2015; 40(3):302-12. PMC: 4994535. DOI: 10.1097/PAS.0000000000000550. View

17.

Hogberg T, Glimelius B, Nygren P . A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol. 2001; 40(2-3):340-60. DOI: 10.1080/02841860151116420. View

18.

Dahm-Kahler P, Borgfeldt C, Holmberg E, Staf C, Falconer H, Bjurberg M . Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG). Gynecol Oncol. 2016; 144(1):167-173. DOI: 10.1016/j.ygyno.2016.10.039. View

19.

Akhtar-Danesh N, Elit L, Lytwyn A . Temporal trends in the relative survival among patients diagnosed with ovarian cancer in Canada 1992-2005: a population-based study. Gynecol Oncol. 2011; 123(2):192-5. DOI: 10.1016/j.ygyno.2011.07.098. View

20.

Peres L, Cushing-Haugen K, Kobel M, Harris H, Berchuck A, Rossing M . Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. J Natl Cancer Inst. 2018; 111(1):60-68. PMC: 6335112. DOI: 10.1093/jnci/djy071. View